260 related articles for article (PubMed ID: 19030985)
1. Synergistic interaction of variants in CHEK2 and BRCA2 on breast cancer risk.
Serrano-Fernández P; Debniak T; Górski B; Bogdanova N; Dörk T; Cybulski C; Huzarski T; Byrski T; Gronwald J; Wokołorczyk D; Narod SA; Lubiński J
Breast Cancer Res Treat; 2009 Sep; 117(1):161-5. PubMed ID: 19030985
[TBL] [Abstract][Full Text] [Related]
2. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.
Weischer M; Bojesen SE; Ellervik C; Tybjaerg-Hansen A; Nordestgaard BG
J Clin Oncol; 2008 Feb; 26(4):542-8. PubMed ID: 18172190
[TBL] [Abstract][Full Text] [Related]
3. Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations.
Cybulski C; Górski B; Huzarski T; Byrski T; Gronwald J; Debniak T; Wokolorczyk D; Jakubowska A; Serrano-Fernández P; Dork T; Narod SA; Lubinski J
J Med Genet; 2009 Feb; 46(2):132-5. PubMed ID: 18930998
[TBL] [Abstract][Full Text] [Related]
4. A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland.
Cybulski C; Wokołorczyk D; Huzarski T; Byrski T; Gronwald J; Górski B; Debniak T; Masojć B; Jakubowska A; van de Wetering T; Narod SA; Lubiński J
Breast Cancer Res Treat; 2007 Mar; 102(1):119-22. PubMed ID: 16897426
[TBL] [Abstract][Full Text] [Related]
5. BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases.
Falchetti M; Lupi R; Rizzolo P; Ceccarelli K; Zanna I; Calò V; Tommasi S; Masala G; Paradiso A; Gulino A; Giannini G; Russo A; Palli D; Ottini L
Breast Cancer Res Treat; 2008 Jul; 110(1):161-7. PubMed ID: 17661168
[TBL] [Abstract][Full Text] [Related]
6. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer.
Cybulski C; Wokołorczyk D; Jakubowska A; Huzarski T; Byrski T; Gronwald J; Masojć B; Deebniak T; Górski B; Blecharz P; Narod SA; Lubiński J
J Clin Oncol; 2011 Oct; 29(28):3747-52. PubMed ID: 21876083
[TBL] [Abstract][Full Text] [Related]
7. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.
Oldenburg RA; Kroeze-Jansema K; Kraan J; Morreau H; Klijn JG; Hoogerbrugge N; Ligtenberg MJ; van Asperen CJ; Vasen HF; Meijers C; Meijers-Heijboer H; de Bock TH; Cornelisse CJ; Devilee P
Cancer Res; 2003 Dec; 63(23):8153-7. PubMed ID: 14678969
[TBL] [Abstract][Full Text] [Related]
8. CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women.
Adank MA; Jonker MA; Kluijt I; van Mil SE; Oldenburg RA; Mooi WJ; Hogervorst FB; van den Ouweland AM; Gille JJ; Schmidt MK; van der Vaart AW; Meijers-Heijboer H; Waisfisz Q
J Med Genet; 2011 Dec; 48(12):860-3. PubMed ID: 22058428
[TBL] [Abstract][Full Text] [Related]
9. Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.
Laitman Y; Kaufman B; Lahad EL; Papa MZ; Friedman E
Isr Med Assoc J; 2007 Nov; 9(11):791-6. PubMed ID: 18085035
[TBL] [Abstract][Full Text] [Related]
10. CHEK2 1100delC and male breast cancer in the Netherlands.
Wasielewski M; den Bakker MA; van den Ouweland A; Meijer-van Gelder ME; Portengen H; Klijn JG; Meijers-Heijboer H; Foekens JA; Schutte M
Breast Cancer Res Treat; 2009 Jul; 116(2):397-400. PubMed ID: 18759107
[TBL] [Abstract][Full Text] [Related]
11. CHEK2 1100delC, IVS2+1G>A and I157T mutations are not present in colorectal cancer cases from Turkish population.
Bayram S; Topaktaş M; Akkız H; Bekar A; Akgöllü E
Cancer Epidemiol; 2012 Oct; 36(5):453-7. PubMed ID: 22521562
[TBL] [Abstract][Full Text] [Related]
12. Common variants of DNA repair genes and malignant melanoma.
Debniak T; Scott RJ; Górski B; Cybulski C; van de Wetering T; Serrano-Fernandez P; Huzarski T; Byrski T; Nagay L; Debniak B; Kowalska E; Jakubowska A; Gronwald J; Wokolorczyk D; Maleszka R; Kładny J; Lubinski J
Eur J Cancer; 2008 Jan; 44(1):110-4. PubMed ID: 18024013
[TBL] [Abstract][Full Text] [Related]
13. Pathology of breast cancer in women with constitutional CHEK2 mutations.
Huzarski T; Cybulski C; Domagała W; Gronwald J; Byrski T; Szwiec M; Woyke S; Narod SA; Lubiński J
Breast Cancer Res Treat; 2005 Mar; 90(2):187-9. PubMed ID: 15803365
[TBL] [Abstract][Full Text] [Related]
14. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.
Meijers-Heijboer H; van den Ouweland A; Klijn J; Wasielewski M; de Snoo A; Oldenburg R; Hollestelle A; Houben M; Crepin E; van Veghel-Plandsoen M; Elstrodt F; van Duijn C; Bartels C; Meijers C; Schutte M; McGuffog L; Thompson D; Easton D; Sodha N; Seal S; Barfoot R; Mangion J; Chang-Claude J; Eccles D; Eeles R; Evans DG; Houlston R; Murday V; Narod S; Peretz T; Peto J; Phelan C; Zhang HX; Szabo C; Devilee P; Goldgar D; Futreal PA; Nathanson KL; Weber B; Rahman N; Stratton MR;
Nat Genet; 2002 May; 31(1):55-9. PubMed ID: 11967536
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor status in CHEK2-positive breast cancers: implications for chemoprevention.
Cybulski C; Huzarski T; Byrski T; Gronwald J; Debniak T; Jakubowska A; Górski B; Wokołorczyk D; Masojć B; Narod SA; Lubiński J
Clin Genet; 2009 Jan; 75(1):72-8. PubMed ID: 19021634
[TBL] [Abstract][Full Text] [Related]
16. The contribution of founder mutations to early-onset breast cancer in French-Canadian women.
Ghadirian P; Robidoux A; Zhang P; Royer R; Akbari M; Zhang S; Fafard E; Costa M; Martin G; Potvin C; Patocskai E; Larouche N; Younan R; Nassif E; Giroux S; Narod SA; Rousseau F; Foulkes WD
Clin Genet; 2009 Nov; 76(5):421-6. PubMed ID: 19863560
[TBL] [Abstract][Full Text] [Related]
17. German populations with infrequent CHEK2*1100delC and minor associations with early-onset and familial breast cancer.
Rashid MU; Jakubowska A; Justenhoven C; Harth V; Pesch B; Baisch C; Pierl CB; Brüning T; Ko Y; Benner A; Wichmann HE; Brauch H; Hamann U;
Eur J Cancer; 2005 Dec; 41(18):2896-903. PubMed ID: 16239104
[TBL] [Abstract][Full Text] [Related]
18. Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations?
Cybulski C; Wokołorczyk D; Kładny J; Kurzawski G; Suchy J; Grabowska E; Gronwald J; Huzarski T; Byrski T; Górski B; D Ecedil Bniak T; Narod SA; Lubiński J
Eur J Hum Genet; 2007 Feb; 15(2):237-41. PubMed ID: 17106448
[TBL] [Abstract][Full Text] [Related]
19. Increased risk of breast cancer associated with CHEK2*1100delC.
Weischer M; Bojesen SE; Tybjaerg-Hansen A; Axelsson CK; Nordestgaard BG
J Clin Oncol; 2007 Jan; 25(1):57-63. PubMed ID: 16880452
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer in patients carrying a germ-line CHEK2 mutation: Outcome after breast conserving surgery and adjuvant radiotherapy.
Meyer A; Dörk T; Sohn C; Karstens JH; Bremer M
Radiother Oncol; 2007 Mar; 82(3):349-53. PubMed ID: 17250914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
